---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Effect on quality measures"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Effect on quality measures. Topics: HEDIS Kidney Health Evaluation for Patients With Diabetes (KED). 1 evidence topic quoted from 1 source."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/effect-on-quality-measures"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Effect on quality measures

<a id="heading-2.1.2.13"></a>

## 2.1.2.13 Effect of Inaxaplin on Quality Measures

<a id="topic-2.1.2.13-1"></a>

### HEDIS Kidney Health Evaluation for Patients With Diabetes (KED)

> “The percentage of persons 18–85 years of age with diabetes (type 1 or type 2) who received a kidney health evaluation”
> “The eGFR test evaluates kidney function; the uACR test evaluates kidney damage.”

Source: [NCQA](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/measures-list/kidney-health-evaluation-for-patients-with-diabetes-ked/)

<a id="topic-2.1.2.13-2"></a>

### Product-specific effect on quality measures

No evidence found.

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
